Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients

Launched by XUANWU HOSPITAL, BEIJING · Oct 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain changes in genes, proteins, and metabolites (which are small molecules produced in our body) may affect patients with drug-resistant epilepsy (DRE). The researchers want to compare brain tissues from people with DRE to those from individuals with normal brain function after a traumatic brain injury (TBI). By understanding these differences, they hope to learn more about what causes epilepsy and find new ways to treat it.

To participate in this study, you need to be between 14 and 60 years old and have drug-resistant epilepsy, which means your seizures do not respond well to standard treatments. You also need to have surgery to implant special electrodes in your brain to monitor your seizures. However, certain conditions like serious heart or liver problems, severe side effects from medications, or a history of substance abuse could prevent you from joining. This trial is currently not recruiting participants, but it aims to provide valuable insights that could lead to better treatments for epilepsy in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 14-60 years old, male or female, Han Chinese;
• • 2. Drug-resistant epilepsy;
• • 3. Required surgical implantation of SEEG electrodes.
• Exclusion Criteria:
• • 1. Progressive encephalopathy or progressive structural damage in the central nervous system;
• • 2. Significant heart, liver, renal insufficiency, and other medical diseases;
• • 3. Severe side effects from taking antiepileptic drugs at the time of enrollment and not inappropriate for SEEG;
• • 4. Significant intellectual disability;
• • 5. A history of alcohol and drug abuse;
• • 6. Any contraindication to MRI.